Supernus Pharmaceuticals (NASDAQ: SUPN) reported Q3 EPS of $0.08, $0.06 better than the analyst estimate of $0.02. Revenue for the quarter came in at $38.6 million versus the consensus estimate of $38.1 million.

For earnings history and earnings-related data on Supernus Pharmaceuticals (SUPN) click here.